WO2023091145A1 - Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity - Google Patents
Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity Download PDFInfo
- Publication number
- WO2023091145A1 WO2023091145A1 PCT/US2021/060228 US2021060228W WO2023091145A1 WO 2023091145 A1 WO2023091145 A1 WO 2023091145A1 US 2021060228 W US2021060228 W US 2021060228W WO 2023091145 A1 WO2023091145 A1 WO 2023091145A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silver
- wound
- bilaminate
- permeaderm
- nylon
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 16
- 229910052709 silver Inorganic materials 0.000 title claims description 62
- 239000004332 silver Substances 0.000 title claims description 62
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims description 59
- 230000001851 biosynthetic effect Effects 0.000 title description 4
- 238000000576 coating method Methods 0.000 claims abstract description 9
- 239000011248 coating agent Substances 0.000 claims abstract 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 69
- 229920001296 polysiloxane Polymers 0.000 claims description 41
- 239000004677 Nylon Substances 0.000 claims description 38
- 229920001778 nylon Polymers 0.000 claims description 38
- 229940071575 silver citrate Drugs 0.000 claims description 37
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 34
- 239000008273 gelatin Substances 0.000 claims description 32
- 229920000159 gelatin Polymers 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 108010010803 Gelatin Proteins 0.000 claims description 31
- 235000019322 gelatine Nutrition 0.000 claims description 31
- 235000011852 gelatine desserts Nutrition 0.000 claims description 31
- 241001116389 Aloe Species 0.000 claims description 26
- 235000011399 aloe vera Nutrition 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 24
- 239000010410 layer Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 230000035876 healing Effects 0.000 claims description 17
- 229910001868 water Inorganic materials 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 8
- 230000001464 adherent effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000035699 permeability Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000003760 magnetic stirring Methods 0.000 claims description 4
- 239000008223 sterile water Substances 0.000 claims description 4
- HGXIBFSXZZKKRV-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;silver;hydrate Chemical compound O.[Ag].[Ag].[Ag].OC(=O)CC(O)(C(O)=O)CC(O)=O HGXIBFSXZZKKRV-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 238000001879 gelation Methods 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 2
- UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 claims 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims 1
- 239000004189 Salinomycin Substances 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 229960002721 mafenide acetate Drugs 0.000 claims 1
- 229960001548 salinomycin Drugs 0.000 claims 1
- 235000019378 salinomycin Nutrition 0.000 claims 1
- 239000002759 woven fabric Substances 0.000 claims 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 abstract description 22
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 80
- 206010052428 Wound Diseases 0.000 description 79
- 239000007789 gas Substances 0.000 description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 238000009472 formulation Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 238000009792 diffusion process Methods 0.000 description 9
- 229960000074 biopharmaceutical Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ZGGDWWSJQXWJON-UHFFFAOYSA-K O.[Ag+3].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-] Chemical compound O.[Ag+3].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-] ZGGDWWSJQXWJON-UHFFFAOYSA-K 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000000774 hypoallergenic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 2
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000013883 Blast injury Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XSLHNXBPPDZDAU-UHFFFAOYSA-M 2-[(e)-2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-n,n,1-trimethylquinolin-1-ium-6-amine;hydroxide Chemical compound [OH-].C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1\C=C\C(=C1C)C=C(C)N1C1=CC=CC=C1 XSLHNXBPPDZDAU-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150049278 US20 gene Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000003397 biobrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960003903 oxygen Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960002778 pyrvinium Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A61F13/01029—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
Definitions
- This invention relates to primary dressings and bandages for both acute and chronic wounds, particularly for burns.
- PermeaDerm has many desirable properties which are described as essential for an Ideal Skin Substitute or primary wound dressing: adherent, long shelf-life at room-temp, transparent, moist healing, conformable, flexible, non-toxic, strong, low-cost, non-biodegradeable membrane oxygenator, sterile, low dressing change and low pain.
- adherent long shelf-life at room-temp
- transparent moist healing
- conformable flexible
- non-toxic strong, low-cost
- non-biodegradeable membrane oxygenator sterile, low dressing change and low pain.
- sterile low dressing change and low pain.
- Adding silver to PermeaDerm provides an important property - broad antimicrobial activity. Silver, a heavy metal can damage good and bad cells. The mode of action is generally protein denaturation.
- the objective here is to include a silver salt in the 3D structure of PermeaDerm at a minimum concentration that effectively kills microbes over a period of time.
- This strategy has intent to kill either endogenous/exogenous microbes inside the 3D structure of PermeaDerm while minimizing damage to autogenous cells and tissue that grow onto the 3D structure of PermeaDerm.
- the US Army Medical Material Activity (USAMMDA) and US Army Institute of Surgical Research (USAISR) has expressed interest in PermeaDerm for use on the battlefield to reduce pain associated with blast injury to soldier’s extremities so they can continue with their battle duties in the field with minimum discomfort.
- PermeaDerm possesses properties important to the USAMMDA and USAISR which are listed above where adherence and pain reduction are critical. The addition of broad antimicrobial activity would satisfy the US Army’s need for a primary wound dressing or skin substitute with optimal properties for their soldiers. In the domestic wound care market; closure with PermeaDerm has been proven successful for both acute and chronic wound management.
- Bacterial contamination is possible from two sources: endogenous to the wound or exogenous to the wound.
- Major risk factor for patients with diabetic foot ulcers is infection, gangrene and subsequent amputation. Cost of care for lower leg amputation is substantial at $52,000 per year for reimbursement.
- Most clinical infections are from microbes endogenous to the wound or microbes already present in the wound.
- PD silicone membrane is 100% impermeable to exogenous microbes except at a slit opening. PD is 99% occlusive therefore a great barrier to exogenous microbes outside the wound.
- Non-adhesive hydrogels Specific to hydrogels which are different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of the present invention.
- the present invention is a new and improved approach to providing a bandage that addresses burn injuries.
- the state-of-art bandages do not possess the new features of the present invention, directed to allowing a measured amount of porosity, including essentially zero porosity, and a lower cost to produce combined with shorter healing/rehabilitation times .
- Wound sites have variable amounts of exudate/transudate/plasma present, from dry to weepy.
- the clinician must cleanly debride the wound, close it and manage wound healing in a moist but not wet environment to achieve optimal results ie for both acute and chronic wounds. This is particularly difficult with complicated structures like hands and feet.
- the present invention provides a dressing that possesses all the properties and attributes of an ideal skin substitute and, in addition, has ‘variable porosity’ controlled by the clinician from zero porosity to what the wound requires.
- the present invention enables the clinician to move the fluid exuding from the wound through the primary dressing into an absorbent secondary dressing without disturbing the kinetics of healing or causing pain to the patient.
- the present invention will have a single layer of biologicals comprised of a hypoallergenic BSE free USP Pharmaceutical grade porcine gelatin, pure Aloe or Aloesin, pure Aloe and BSE free porcine gelatin, or a mixture of pure Aloe, BSE free gelatin and ECM interact with the wound to stimulate the rate of healing while adherent to the wound.
- the bio-coat layer is deposited directly on the nylon side of the “variable porosity” silicone/nylon surface and is stable for over five years at room temperature.
- ECM extra-cellular matrix
- Previous wound dressings and skin substitutes contain gelatin, a pure Aloe component, chondroitin 4 & 6 sulfate, and vitamin C & E. In contrast the current dressing will have two layers of biologicals applied in separate spraying operations as described above.
- the first coat will contact the wound after the second coat of hypoallergenic bovine spongiform encephalopathy (BSE) - free United States Pharmaceutical (USP) - grade porcine gelatin interacts with fibrin in the wound to achieve early adherence,
- BSE bovine spongiform encephalopathy
- USP United States Pharmaceutical
- Human wounds vary in the following ways depending on location: relatively flat, convex, or concave surface; and vary in movement from minimal to a lot (diaphragm). Most difficult location to achieve adherence are convex wounds where there is movement (axilla, upper abdomen, etc.). Irregular depth wounds such as ulcers (DFU, VLU - diabetic foot ulcer and venous leg ulcer) require prompt closure requiring excellent compliance, stretchability or elongation.
- DFU ulcers
- VLU - diabetic foot ulcer and venous leg ulcer require prompt closure requiring excellent compliance, stretchability or elongation.
- a thicker 3D structure (average thickness 0.0080” with STDEV 0.0008”) for PDG (PermeaDerm® glove) provides additional advantages over normal thickness PDG with respect to greater circumferential elongation and fit in the web spaces giving the clinician greater room for error during the fitting process. Once properly fitted, PDG will enable rapid rehabilitation without pain to regain full range of motion and will minimize interference with the healing process yielding excellent aesthetic and functional results. PDB and PDG (PermeaDerm® Chronic) would clinically benefit from both greater adherence and greater elongation/conformability.
- PermeaDerm has been proven to possess a room temperature shelflife of at least five years. PermeaDerm with silver is expected to have a shelf-life of more than five years at room temperature based on known properties of Kodak film which contain gelatin-silver as the active component of photographic film. “At a room temperature of 24°C (75°F) or colder, with the relative humidity no higher than 60 percent, and if the print was properly processed, the dyes should remain relatively stable for about 20 years.”
- First step is formulating a stable biocoat of Aloe/gelatin and subsequent drying the same - it is stable because of PermeaDerm’s real-time shelf-life properties at room-temperature for at least five years.
- PermeaDerm Essentially the only biodegradable component of PermeaDerm over time is Aloe and gelatin, the biological components of the product (less than 2% of the PermeaDerm
- PermeaDerm is the stable synthetic components - silicone/nylon membrane).
- Second step is application of a higher concentration of silver citrate to the 3D structure over the top of the standard Aloe/gelatin biocoat - defined in the Silver PermeaDerm Formulation.
- Adherence in wounds can be compromised by fluid accumulation beneath the PermeaDerm - solution is various slits that can be enlarged by clinician to enable wound fluid to move from beneath the PermeaDerm into an absorbent secondary dressing which can be periodically replaced without compromise of adherence or wound healing
- PermeaDerm Use of PermeaDerm is never compromised by accumulation of gases (oxygen, carbon dioxide, water) beneath PermeaDerm.
- gases oxygen, carbon dioxide, water
- the area of PermeaDerm containing no slits is close to 99%. Gases can dissolve into solid silicone and diffuse through based on a concentration gradient:
- Diffusion is the gradual mixing of gases due to the motion of their component particles even in the absence of mechanical agitation such as stirring driven by gases at a higher concentration always moving to a lower concentration.
- a membrane oxygenator separates blood from air. Typically the oxygen concentration in air is higher than in blood and the oxygen always moves toward a lower concentration - from air to blood.
- Silicone chemically known as polydimethylsiloxane (PDMS), is among the most gas permeable dense polymeric membrane materials available . Gases permeate silicone by a solution / diffusion mechanism, whereby the rate of gas permeation is directly proportional to the product of solubility of the gas, and the rate of diffusion of the dissolved gas in silicone.
- the permeability coefficient is a parameter defined as the transport flux of a gas (rate of gas permeation per unit area), per unit transmembrane driving force, per unit membrane thickness.
- OxyBand Wound DressingTM is the only FDA-approved wound dressing proven to continuously deliver pure oxygen to damaged tissue for up to 5 days.
- OxyBand Wound DressingTM is a patented medical technology with a directionally permeable gas-emitting reservoir inside of the dressing.
- OxyBand Wound DressingTM Food and Drug Administration FDA 510(k), K043063, provides oxygen to wounds for up to 5 days.
- the oxygen is pre packaged and in a proprietary method, diffused into the patented reservoir system inside of the OxyBand Wound DressingTM.
- the pre-filled multi-layer, OxyBand Wound DressingTM comes pre-filled with high levels of oxygen between the layers.
- OxyBand Wound DressingTM incorporates a barrier layer that holds the oxygen, in the vicinity, of the wound, and a permeable or porous layer that allows oxygen to diffuse into the wound.
- the dressing acts like an oxygen reservoir, allowing the wound to utilize as much oxygen as needed, and continues to supply oxygen on demand to the wound as the wound consumes oxygen from the wound fluid.
- Oxygen generating wound dressing US Patent 5,792,090 Aug 11, 1998. Abstract: The healing of surface wounds, including burns, is facilitated by increasing the wound oxygen tension through the application of an oxygen-generating wound dressing which renewably and non-sustainingly chemically generates oxygen.
- the wound dressing contains an oxygen permeable membrane and an oxygen supply solution reservoir adapted to receive an aqueous liquid capable of supplying oxygen through chemical reaction.
- the aqueous liquid contains hydrogen peroxide and the reservoir contains an immobilized solid hydrogen peroxide decomposition catalyst such as manganese dioxide.
- the solid catalyst may be contained within a hydrogel, an open-celled polymeric foam, or a biosynthetic foam such as a collagen foam.
- the oxygen-generating wound dressing may be applied over an intermediate hydrogel occlusive wound covering such as an alginate.
- the present invention is similar in composition to earlier skin substitutes in that they each have a thin silicone component and an underlying 3D thin knitted nylon component.
- the present invention differs from its ancestors in that it has “variable porosity” controlled by the clinician; the slit width in the thin silicone will be essentially zero (with no stretch, in relaxed mode) to a higher porosity (proportional to the stretch applied).
- the present invention differs from prior art in the composition of biological coatings applied to both components and how these coatings interact with the wound over time.
- the preferred embodiment of the invention designed for burns a regular pattern with slits on the silicone surface parallel to each other in the same row is presented.
- the slits made in the silicone are approximately. 0.125” long with a space of 0.50”, between the slits; off-set parallel rows of slits are 0.25” apart.
- the silicone/nylon membrane can be stretched in a direction perpendicular to the slit orientation and the slits will open. Porosity therefore increases proportionally to the amount of stretch applied. Obviously, there is a maximum amount of stretching of the preferred embodiment before the dressing fails. IFU (instructions for use) describe a maximum of 20% elongation, well below the breaking point.
- the use of the present invention has a large benefit because it is stable on the wound and possesses biologicals that aid in the healing process.
- the present invention will have a first layer of biologicals comprised of a hypoallergenic BSE free USP Pharmaceutical grade porcine gelatin, pure Aloe or Aloesin, pure Aloe and BSE free porcine gelatin, or a mixture of pure Aloe, BSE free porcine gelatin and ECM interact with the wound to stimulate the rate of healing while adherent to the wound.
- a hypoallergenic BSE free USP Pharmaceutical grade porcine gelatin, pure Aloe or Aloesin, pure Aloe and BSE free porcine gelatin, or a mixture of pure Aloe, BSE free porcine gelatin and ECM interact with the wound to stimulate the rate of healing while adherent to the wound.
- the biologicals are applied to the knitted nylon side of the present embodiment.
- the biologicals can be applied to the silicone layer as well.
- the preferred embodiment is the Gen3 PermeaDerm with average thickness of 0.0080” and STDEV of 0.0008” which results in Optimal adherence.
- the present invention also claims superior oxygenation for wounds, due to its structure.
- Gases permeate silicone by a solution / diffusion mechanism whereby the rate of gas permeation is directly proportional to the product of solubility of the gas, and the rate of diffusion of the dissolved gas in silicone.
- the permeability coefficient is a parameter defined as the transport flux of a gas (rate of gas permeation per unit area), per unit transmembrane driving force, per unit membrane thickness.
- the permeability coefficient for various gases and vapors in silicone is presented in the table below (Membrane Basics I PermSelect-MedArray). Permeability coefficients: oxy- gen 600, Carbon dioxide 3,250 and water 36,000.
- the gases of clinical interest are oxygen, carbon dioxide and water.
- Diffusion rate The rate of diffusion (diffusion of gases through silicone membranes - Bing) through the silicone membrane is inversely proportional to the thickness of the membrane, any factor that increases the thickness to more than two to three times normal can interfere significantly with normal respiratory exchange of gases.
- Bilaminate membranes of silicone/nylon The art of making strong and thin membranes of silicone and nylon were accomplished in 1978 with invention of Biobrane and continued with AWBAT 2008, and PermeaDerm 2013. The method is a precision knife blade of a dilute dispersion of dimethyl-silicone in xylene onto a perfectly flat surface, then combined with a precise knitted nylon structure, and then cured to make the silicone a solid. Gases (oxygen, carbon dioxide and water) rapidly dissolve in the solid silicone membrane as they move from a higher concentration to a lower concentration. The achievement of silicone/nylon membranes with thicknesses of less than one mil enhances the ability of gases to diffuse through the thin, strong solid silicone membrane. The clinical significance of higher oxygen and lower carbon dioxide is apparent faster healing of chronic wounds which have defective vascular supply.
- PermeaDerm has been proven to possess a room temperature shelf-life of at least five years. PermeaDerm with silver is expected to have a shelf-life of more than five years at room temperature based on known properties of Kodak film which contain gelatin-silver as the active component of photographic film. “At a room temperature of 24°O (75°F) or colder, with the relative humidity no higher than 60 percent, and if the print was properly processed, the dyes should remain relatively stable for about 20 years.”
- the formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system.
- the first step is our Standard method of adding a gelatin/Aloe biocoat (6 microliter per sq. cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol.
- the 2 nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
- the formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system.
- the first step is our Standard method of adding a gelatin/Aloe biocoat (6 microlite per sq. cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol.
- a gelatin/Aloe biocoat (6 microlite per sq. cm. of PermeaDerm)
- the 2 nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
- Gen 1 1 .0 sq. cm. of Genl (average thickness 0.0043” or 0.0109 cm) has a volume of 0.0109 ml containing 0.108 ug of silver ion or a concentration of 9.908 ppm silver. This provides 9.908 ug silver ion per ml of 3D structure.
- Gen 3 1 .0 sq. cm. of Gen3 (average thickness 0.0080” or 0.0203 cm) has a volume of 0.0203 ml containing 0.108 ug of silver ion or a concentration of 5.32 ppm silver. This provides 5.32 ug silver ion per ml of 3D structure.
- the Silver Citrate PRDM C 5” x 57Lot SO 63331 RD pads were digested in standard manner and analyzed by ICPMS to determine silver content per cm2 in the 5” x 5” pads. Result:
- Test 1 0.000580 ug Silver I cm 2 Test 2: 0.000580 ug Silver I cm 2 Test 3: 0.000414 ug Silver I cm 2 Test 4: 0.000580 ug Silver/ cm 2
- the expected amount of silver I cm 2 on the pads tested is 0.108 ug Silver/ cm 2 .
- the recovery was approximately 0.5%% of the expected amount using this method. We were not sure if the low recovery was due to the sample being low in silver or if the testing methodology was in error. Other digestion methods produced similar low silver concentration results in the pads tested (Tests 5 to 9 results similar or less than tests 1-4)).
- Test 10 0.0955 ug Silver/ cm 2 . This is 88% of the expected silver in the sample tested.
- Test 11 Spiked 90ug of Silver into sample: 79 ug recovered of the 90ug spiked (87.8% recovery).
- the Silver Citrate PRDM C 5” x 5”/Lot SO 63331 RD product has silver in the form of silver chloride which will still effectively release silver ion but may require a higher amount of silver citrate to provide the antibiotic efficacy in a timely manner.
- the Silver Citrate PRDM C 5” x 57Lot SO 63331 RD was placed in a tube with 25 ml_s DI water and solicited for 1 hour. After solication, the membrane was transferred into a beaker and heated to boiling for 30 minutes with constant stirring. The volume was reduced to 10 ml_s and split into 2 x 5 ml_s portions. To one of the tubes an additional 45 ug of silver was added. The two samples were then tested against an inoculum of Staphylococcus Epidermis for 7 days to investigate the reduction in colonies.
- Silver ion is a double-edge sword in that it can kill host cells as well as unwanted microbes that interfere with wound healing.
- the FDA requires sufficient silver to effectively reduce the microbial bioburden to enable efficient healing.
- Goa I kill required amount of microbes while doing minimal harm to host tissue.
- a silver Citrate/Citric Acid Solution is prepared; a. Dissolve 2.24 grams of USP Citric Acid in 9 ml. of distilled water. b. Add 72.0 mg of Silver Citrate Hydrate and mix to dissolve. c. Add above mixture to ml. volumetric flask and add distilled water to volume.
- Silver PermeaDerm prototypes using the original formulation was manufactured and sterilized with 25 kGy of E Beam the apparent amount of silver present was substantially lower than expected. A concern that the silver might irreversibly be bound to the gelatin or Aloe and unavailable to reduce bacterial bioburden in the wound or in the 3D structure of Silver PermeaDerm.
- Preferred formulation for Silver PermeaDerm is a two-step process with following objectives:
- the formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system.
- the first step is our Standard method of adding a gelatin/Aloe biocoat (6 microlite per sq. cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol.
- the 2nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
- the present invention is a wound closure device that provides an oxygenated, moist but not wet healing environment which by not being wet minimizes bacterial proliferation and optimizes growth of healthy host tissue.
- the presence of silver ion in the 3D structure of PermeaDerm further enables reduction of harmful bacteria and other microbes.
- the new, preferred formulation contained 5X the amount of silver as the original formulation and effectively reduced the bacterial level by 99.9% as compared to the original earlier formulation with 97.9% reduction.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
Abstract
An improved dressing is presented which enables quicker wound closure and a lower anesthesia requirement, comprised of an improved prior-art skin-substitute. The improvements consist of variations in the thickness of the woven portion of the dressing, to increase wound adherence and use of a silver ion antimicrobial coating.
Description
Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity
RELATED APPLICATIONS
This application is a Continuation-in-Part of PCT Application PCT/US20/37962 filed June 16, 2020, and that application is included here by reference in its entirety.
FIELD OF THE INVENTION
This invention relates to primary dressings and bandages for both acute and chronic wounds, particularly for burns.
BACKGROUND OF THE INVENTION
Background for a primary wound dressing of skin substitute containing broad antimicrobial activity: Over the past 20 years numerous wound dressings containing silver have been introduced to the wound care market. Examples are: Acticoat, Tegaderm w/ Ag, Aquacel-Ag, Maxorb Extra Ag, Melgisorb, and so on. Silver in wound dressings is used in various forms, usually as a silver salt and reported as ppm or grams added per unit area/volume of the dressing.
PermeaDerm has many desirable properties which are described as essential for an Ideal Skin Substitute or primary wound dressing: adherent, long shelf-life at room-temp, transparent, moist healing, conformable, flexible, non-toxic, strong, low-cost, non-biodegradeable membrane oxygenator, sterile, low dressing change and low pain. Adding silver to PermeaDerm provides an important property - broad antimicrobial activity.
Silver, a heavy metal can damage good and bad cells. The mode of action is generally protein denaturation.
The objective here is to include a silver salt in the 3D structure of PermeaDerm at a minimum concentration that effectively kills microbes over a period of time. This strategy has intent to kill either endogenous/exogenous microbes inside the 3D structure of PermeaDerm while minimizing damage to autogenous cells and tissue that grow onto the 3D structure of PermeaDerm. The US Army Medical Material Activity (USAMMDA) and US Army Institute of Surgical Research (USAISR) has expressed interest in PermeaDerm for use on the battlefield to reduce pain associated with blast injury to soldier’s extremities so they can continue with their battle duties in the field with minimum discomfort. PermeaDerm possesses properties important to the USAMMDA and USAISR which are listed above where adherence and pain reduction are critical. The addition of broad antimicrobial activity would satisfy the US Army’s need for a primary wound dressing or skin substitute with optimal properties for their soldiers. In the domestic wound care market; closure with PermeaDerm has been proven successful for both acute and chronic wound management.
The incidence of infection complication is low due to the variable porosity of PermeaDerm and its ability to minimize wound fluid accumulation beneath PermeaDerm. Addition of a silver salt (silver citrate)
adds broad antimicrobial activity to the wide range of properties and benefits already provided by PermeaDerm.
Bacterial contamination is possible from two sources: endogenous to the wound or exogenous to the wound. Major risk factor for patients with diabetic foot ulcers is infection, gangrene and subsequent amputation. Cost of care for lower leg amputation is substantial at $52,000 per year for reimbursement. Most clinical infections are from microbes endogenous to the wound or microbes already present in the wound. PD’s silicone membrane is 100% impermeable to exogenous microbes except at a slit opening. PD is 99% occlusive therefore a great barrier to exogenous microbes outside the wound.
Relevant Prior Art - the following list is a summary of prior art for the science of using silver for wound care, with some comments:
US201 60030476 VACHON DAVID J et al. “Compositions, methods and devices for promoting wound healing and reducing infection.” Similar objective to kill microbes contaminating the wound while minimizing damage to autogenous tissue. Generally describes numerous materials that silver species can be incorporated into. Does speak to silver concentration effect in killing microbes and autogenous skin cells. Does not describe a gelatin/aloe material for combining silver with. And does not speak to shelf-life properties of a wound dressing and how a silver-gelatin salt (like Kodak film) would improve room-temperature shelf-life.
US20070009580 DICOSMO FRANK et al. “Non-adhesive hydrogels” Specific to hydrogels which are different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of the present invention. US10350219 KARANDIKAR BHALCHANDRA M. “Antimicrobial compositions and methods of making the same”. Specific to hydrogels different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of PermeaDerm.
US6808738 DITIZIO VALERIO et al. “Method of making anti-microbial polymeric surfaces “ Specific to hydrogels which is different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of The present invention.
US9937156 SMALL ERIC M et al. “Modulation of mrtf-a activity in pathologic fibrosis and wound healing”. Specific to acrylate-modified silicon which is different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of the present invention.
US201 80008742 HOGGARTH ANDREW et al. “ Composition for a wound dressing”. Fairly general wound dressing which is different than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of the present invention.
US201 2031 8262 LEE ETHAN et al. “Pyrvinium wound treatment methods and devices”. Fairly general wound dressing which is different
than our bilaminate of silicon/nylon with bio-coat of gelatin/aloe onto the 3D structure of the present invention.
SUMMARY OF THE INVENTION
The present invention is a new and improved approach to providing a bandage that addresses burn injuries. The state-of-art bandages do not possess the new features of the present invention, directed to allowing a measured amount of porosity, including essentially zero porosity, and a lower cost to produce combined with shorter healing/rehabilitation times .
The goal was to create a more effective biosynthetic bandage for burns management. . A hydrophilic/hygroscopic moist, but not wet, wound healing environment which enhances healing.
Wound sites have variable amounts of exudate/transudate/plasma present, from dry to weepy. The clinician must cleanly debride the wound, close it and manage wound healing in a moist but not wet environment to achieve optimal results ie for both acute and chronic wounds. This is particularly difficult with complicated structures like hands and feet.
The present invention provides a dressing that possesses all the properties and attributes of an ideal skin substitute and, in addition, has ‘variable porosity’ controlled by the clinician from zero porosity to what the wound requires. The present invention enables the clinician to move the fluid exuding from the wound through the primary dressing into an
absorbent secondary dressing without disturbing the kinetics of healing or causing pain to the patient.
The present invention will have a single layer of biologicals comprised of a hypoallergenic BSE free USP Pharmaceutical grade porcine gelatin, pure Aloe or Aloesin, pure Aloe and BSE free porcine gelatin, or a mixture of pure Aloe, BSE free gelatin and ECM interact with the wound to stimulate the rate of healing while adherent to the wound. The bio-coat layer is deposited directly on the nylon side of the “variable porosity” silicone/nylon surface and is stable for over five years at room temperature.
In vitro, the Aloe component has been demonstrated to cause a variety of cells to attach and proliferate; as well as increase synthesis of collagen and alpha smooth muscle actin. ECM (extra-cellular matrix) may be added to the biologicals described above and is a mixture from human fibroblasts that is known to cause rapid cell proliferation and tissue growth. Previous wound dressings and skin substitutes, as taught in US Pat. 7,815,931 contain gelatin, a pure Aloe component, chondroitin 4 & 6 sulfate, and vitamin C & E. In contrast the current dressing will have two layers of biologicals applied in separate spraying operations as described above. The first coat will contact the wound after the second coat of hypoallergenic bovine spongiform encephalopathy (BSE) - free United States Pharmaceutical (USP) - grade porcine gelatin interacts with fibrin in the wound to achieve early adherence, The second coat of biologicals stimulates the healing process during the interval where the dressing
invention is in contact with the wound and is stable requiring 100 degree water for 30 minutes to remove from the “variable porosity” silicone/nylon surface.
Human wounds vary in the following ways depending on location: relatively flat, convex, or concave surface; and vary in movement from minimal to a lot (diaphragm). Most difficult location to achieve adherence are convex wounds where there is movement (axilla, upper abdomen, etc.). Irregular depth wounds such as ulcers (DFU, VLU - diabetic foot ulcer and venous leg ulcer) require prompt closure requiring excellent compliance, stretchability or elongation.
If slow-healing ulcers (DFU, VLU, PU - pressure ulcer) are not closed promptly infection complications often occur and potential loss of limb and compromise of lifestyle is at risk. Clinical preference is current PDC (average thickness is 0.0080” with STDEV of 0.0008”) for protection of widely meshed autograft where maximization of healing (definitive closure) of the interstices is desired. Too much adherence (greater than 50 gm per sq. cm. at 5 hours or 0.0048” thick) will slow interstices healing of a widely meshed autograft.
A thicker 3D structure (average thickness 0.0080” with STDEV 0.0008”) for PDG (PermeaDerm® glove) provides additional advantages over normal thickness PDG with respect to greater circumferential elongation and fit in the web spaces giving the clinician greater room for
error during the fitting process. Once properly fitted, PDG will enable rapid rehabilitation without pain to regain full range of motion and will minimize interference with the healing process yielding excellent aesthetic and functional results. PDB and PDG (PermeaDerm® Chronic) would clinically benefit from both greater adherence and greater elongation/conformability.
There is a Regulatory advantage (FDA approval) based on use of same material (15/1 denier virgin nylon filament) to increase thickness of 3D structure of PermeaDerm® product as opposed to use of a different denier of virgin nylon filament (example 15/2, 15/3, 18/3 denier). Estimated thickness using SEM: 15/1 denier about 0.0069” and 18/3 denier about 0.014”. 3D structure of 18/3 denier is about 103% (more than double) thicker than 15/1 denier.
PermeaDerm has been proven to possess a room temperature shelflife of at least five years. PermeaDerm with silver is expected to have a shelf-life of more than five years at room temperature based on known properties of Kodak film which contain gelatin-silver as the active component of photographic film. “At a room temperature of 24°C (75°F) or colder, with the relative humidity no higher than 60 percent, and if the print was properly processed, the dyes should remain relatively stable for about 20 years.”
There is a further goal to Incorporate silver ion into the 3D matrix of the present invention at the lowest concentration where antimicrobial activity is
effective (kills 100,000 microbes). We want a 3 uL (2nd biocoat of Silver Citrate/Citric Acid solution Spray Solution) to dispense 0.54 ug of silver ion or 0.885 ug of silver citrate monohydrate per each square cm surface of PermeaDerm 3D which faces the wound.
Key tactic here is minimizing the interaction of silver with Aloe and gelatin, therefore we use a two-step formulation process:
First step is formulating a stable biocoat of Aloe/gelatin and subsequent drying the same - it is stable because of PermeaDerm’s real-time shelf-life properties at room-temperature for at least five years. Essentially the only biodegradable component of PermeaDerm over time is Aloe and gelatin, the biological components of the product (less than 2% of the PermeaDerm
- over 98% of PermeaDerm is the stable synthetic components - silicone/nylon membrane).
Second step is application of a higher concentration of silver citrate to the 3D structure over the top of the standard Aloe/gelatin biocoat - defined in the Silver PermeaDerm Formulation.
Wounds closed with a biocoated silicone/nylon membrane needs to be adherent, without adherence it will not work.
Adherence in wounds can be compromised by fluid accumulation beneath the PermeaDerm - solution is various slits that can be enlarged by clinician to enable wound fluid to move from beneath the PermeaDerm into
an absorbent secondary dressing which can be periodically replaced without compromise of adherence or wound healing
Use of PermeaDerm is never compromised by accumulation of gases (oxygen, carbon dioxide, water) beneath PermeaDerm. The area of PermeaDerm containing no slits is close to 99%. Gases can dissolve into solid silicone and diffuse through based on a concentration gradient:
Diffusion: Diffusion is the gradual mixing of gases due to the motion of their component particles even in the absence of mechanical agitation such as stirring driven by gases at a higher concentration always moving to a lower concentration. A membrane oxygenator separates blood from air. Typically the oxygen concentration in air is higher than in blood and the oxygen always moves toward a lower concentration - from air to blood.
Silicone : chemically known as polydimethylsiloxane (PDMS), is among the most gas permeable dense polymeric membrane materials available . Gases permeate silicone by a solution / diffusion mechanism, whereby the rate of gas permeation is directly proportional to the product of solubility of the gas, and the rate of diffusion of the dissolved gas in silicone. The permeability coefficient is a parameter defined as the transport flux of a gas (rate of gas permeation per unit area), per unit transmembrane driving force, per unit membrane thickness.
The following are two wound oxygenation approaches in the relevant literature. They are easily distinguishable from the present invention:
OxyBand Wound Dressing™ is the only FDA-approved wound dressing proven to continuously deliver pure oxygen to damaged tissue for up to 5 days. OxyBand Wound Dressing™ is a patented medical technology with a directionally permeable gas-emitting reservoir inside of the dressing. OxyBand Wound Dressing™, Food and Drug Administration FDA 510(k), K043063, provides oxygen to wounds for up to 5 days. The oxygen is pre packaged and in a proprietary method, diffused into the patented reservoir system inside of the OxyBand Wound Dressing™. The pre-filled multi-layer, OxyBand Wound Dressing™, comes pre-filled with high levels of oxygen between the layers. OxyBand Wound Dressing™ incorporates a barrier layer that holds the oxygen, in the vicinity, of the wound, and a permeable or porous layer that allows oxygen to diffuse into the wound. The dressing acts like an oxygen reservoir, allowing the wound to utilize as much oxygen as needed, and continues to supply oxygen on demand to the wound as the wound consumes oxygen from the wound fluid.
Oxygen generating wound dressing US Patent 5,792,090 Aug 11, 1998. Abstract: The healing of surface wounds, including burns, is facilitated by increasing the wound oxygen tension through the application of an oxygen-generating wound dressing which renewably and non-sustainingly chemically generates oxygen. The wound dressing contains an oxygen permeable membrane and an oxygen supply solution reservoir adapted to receive an aqueous liquid capable of supplying oxygen through chemical reaction. Preferably, the aqueous liquid contains hydrogen peroxide and the
reservoir contains an immobilized solid hydrogen peroxide decomposition catalyst such as manganese dioxide. The solid catalyst may be contained within a hydrogel, an open-celled polymeric foam, or a biosynthetic foam such as a collagen foam. The oxygen-generating wound dressing may be applied over an intermediate hydrogel occlusive wound covering such as an alginate.
DETAILED DESCRIPTION
The present invention is similar in composition to earlier skin substitutes in that they each have a thin silicone component and an underlying 3D thin knitted nylon component. The present invention differs from its ancestors in that it has “variable porosity” controlled by the clinician; the slit width in the thin silicone will be essentially zero (with no stretch, in relaxed mode) to a higher porosity (proportional to the stretch applied).
In addition, the present invention differs from prior art in the composition of biological coatings applied to both components and how these coatings interact with the wound over time.
The preferred embodiment of the invention designed for burns, a regular pattern with slits on the silicone surface parallel to each other in the same row is presented. The slits made in the silicone are approximately. 0.125” long with a space of 0.50”, between the slits; off-set parallel rows of slits are 0.25” apart.
In this configuration the silicone/nylon membrane can be stretched in a direction perpendicular to the slit orientation and the slits will open. Porosity therefore increases proportionally to the amount of stretch applied. Obviously, there is a maximum amount of stretching of the preferred
embodiment before the dressing fails. IFU (instructions for use) describe a maximum of 20% elongation, well below the breaking point.
The use of the present invention has a large benefit because it is stable on the wound and possesses biologicals that aid in the healing process.
The present invention will have a first layer of biologicals comprised of a hypoallergenic BSE free USP Pharmaceutical grade porcine gelatin, pure Aloe or Aloesin, pure Aloe and BSE free porcine gelatin, or a mixture of pure Aloe, BSE free porcine gelatin and ECM interact with the wound to stimulate the rate of healing while adherent to the wound.
The biologicals are applied to the knitted nylon side of the present embodiment. Optionally, the biologicals can be applied to the silicone layer as well.
The preferred embodiment is the Gen3 PermeaDerm with average thickness of 0.0080” and STDEV of 0.0008” which results in Optimal adherence.
Improved PermeaDerm product with addition of silver citrate:
Stability at room-temp: Current Biocoat of PermeaDerm has been proven to possess a room temperature shelf-life of at least five years. PermeaDerm with silver is expected to have a shelf-life of more than five years at room temperature based on known properties of Kodak film which contain gelatin-silver as the active component of photographic film. “At a room temperature of 24°C (75°F) or colder, with the relative humidity no higher than 60
percent, and if the print was properly processed, the dyes should remain relatively stable for about 20 years. (This dye stability estimate is based on EASTMAN Color Print Film, manufactured in 1990.”)
Clinical and US Army need for a skin substitute with broad antimicrobial activity: Over the past 20 years numerous wound dressings containing silver have been introduced to the wound care market. Examples are: Acti- coat, Tegaderm w/ Ag, Aquacel-Ag, Maxorb Extra Ag, Melgisorb, and so on. PermeaDerm has many desirable properties which are described as essential for an Ideal Skin Substitute: adherent, long shelf-life at room-temp, transparent, moist healing, conformable, flexible, non-toxic, strong, low- cost, membrane oxygenator, sterile, low dressing change, and low pain. Adding silver to PermeaDerm provides an important property - broad antimicrobial activity.
The present invention also claims superior oxygenation for wounds, due to its structure. Gases permeate silicone by a solution / diffusion mechanism, whereby the rate of gas permeation is directly proportional to the product of solubility of the gas, and the rate of diffusion of the dissolved gas in silicone. The permeability coefficient is a parameter defined as the transport flux of a gas (rate of gas permeation per unit area), per unit transmembrane driving force, per unit membrane thickness. The permeability coefficient for various gases and vapors in silicone is presented in the table below (Membrane Basics I PermSelect-MedArray). Permeability coefficients: oxy-
gen 600, Carbon dioxide 3,250 and water 36,000. The gases of clinical interest are oxygen, carbon dioxide and water.
Diffusion rate: The rate of diffusion (diffusion of gases through silicone membranes - Bing) through the silicone membrane is inversely proportional to the thickness of the membrane, any factor that increases the thickness to more than two to three times normal can interfere significantly with normal respiratory exchange of gases.
Bilaminate membranes of silicone/nylon: The art of making strong and thin membranes of silicone and nylon were accomplished in 1978 with invention of Biobrane and continued with AWBAT 2008, and PermeaDerm 2013. The method is a precision knife blade of a dilute dispersion of dimethyl-silicone in xylene onto a perfectly flat surface, then combined with a precise knitted nylon structure, and then cured to make the silicone a solid. Gases (oxygen, carbon dioxide and water) rapidly dissolve in the solid silicone membrane as they move from a higher concentration to a lower concentration. The achievement of silicone/nylon membranes with thicknesses of less than one mil enhances the ability of gases to diffuse through the thin, strong solid silicone membrane. The clinical significance of higher oxygen and lower carbon dioxide is apparent faster healing of chronic wounds which have defective vascular supply.
Use of SEM to illustrate the thickness of the PermeaDerm solid silicone membrane - about 0.0003” thick or extremely thin which functions well as a membrane oxygenator (attached PD Thickness).
The US Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Institute of Surgical Research (USAISR) have expressed interest in PermeaDerm for use on the battlefield to reduce pain associated with blast injury so they can continue with their battle duties with minimum discomfort. PermeaDerm w/ silver would be ideal to quickly close battlefield wounds until the soldier can be treated later in a hospital. Properties important to the USAMMDA and USAISR are listed above plus antimicrobial activity. In the domestic wound care market; closure with PermeaDerm is already successful for acute and chronic wound management. PermeaDerm w/ silver adds another very important benefit: broad antimicrobial activity.
PermeaDerm has been proven to possess a room temperature shelf-life of at least five years. PermeaDerm with silver is expected to have a shelf-life of more than five years at room temperature based on known properties of Kodak film which contain gelatin-silver as the active component of photographic film. “At a room temperature of 24°O (75°F) or colder, with the relative humidity no higher than 60 percent, and if the print was properly processed, the dyes should remain relatively stable for about 20 years.”
The formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system. The first step is our Standard method of adding a gelatin/Aloe biocoat (6 microliter per sq. cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol. After the application of the 1st gelatin/Aloe biocoat and drying
(normal protocol) the 2nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
Methods, Results and Conclusions: Desire 3 uL (2nd biocoat of Silver Citrate/Citric Acid
Desire 3 uL (2nd biocoat of Silver Citrate/Citric Acid solution Spray Solution) to dispense 0.54 ug of silver ion or 0.885 ug of silver citrate monohydrate per each square cm surface of PermeaDerm 3D which faces the wound. This concentration is enough to kill 100,000 colony forming units per ml Staphylococcus epidermis at 7, 14 and 21 days. The solution appears stable, has minimal turbidity (as measured at 660 nm) and the silver ion concentration is constant over at least a one month. The formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system. The first step is our Standard method of adding a gelatin/Aloe biocoat (6 microlite per sq. cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol. After the application of the 1st gelatin/Aloe biocoat and drying (normal protocol) the 2nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
Procedure for Preparation and Stability Characterization of 250 ml_ of Silver Citrate/Citric Acid Solution
Aim: to make 250 ml_ of Silver Citrate Solution (to deliver 5x the amount (as opposed to formulation on October 27, 2020) of silver ion (0.54 ug per sq. cm in 3 uL)
Record weight (+/- 1 %) of:
1 . Beaker plus magnetic stirring bar
2. Sterile water 250 g
3. Silver citrate 74.15 mg
4. USP Citric Acid 56.0 gm
Procedure (follow standard Trelleborg Batch Record Shop Oder instructions and record keeping)
1. Add 200 ml_ of H2O to beaker w/ stirring bar. Keep constant stirring.
2. Gradually add 56.00 g of citric acid until fully dissolved
3. Gradually add 74.15 mg of silver citrate until fully dissolved
4. When dissolved, add to 250 ml_ volumetric flask and bring to 250 ml_ volume with distilled water.
When complete, store at refrigerated temperature (4°C ± 1 °C) for 30 days. After 30 days, filter and weigh filtrate to determine any precipitation. Also, observe solution for cloudiness or any other signs of precipitation of the silver citrate.
Preferred Embodiment:
Methods, Results and Conclusions: Desire 6 uL of Silver PermeaDerm BioCoat Spray Solution to dispense 0.108 ug of silver ion or 0.177 ug of silver citrate monohydrate per each square cm surface of PermeaDerm 3D which faces the wound. This concentration is enough to kill 100,000 colony forming units per ml Staphylococcus epidermis at 7, 14 and 21 days. The solution appears stable, has minimal turbidity (as measured at 660 nm) and the silver ion concentration is constant over at least a one month.
Gen 1 : 1 .0 sq. cm. of Genl (average thickness 0.0043” or 0.0109 cm) has a volume of 0.0109 ml containing 0.108 ug of silver ion or a concentration of 9.908 ppm silver. This provides 9.908 ug silver ion per ml of 3D structure.
Gen 3: 1 .0 sq. cm. of Gen3 (average thickness 0.0080” or 0.0203 cm) has a volume of 0.0203 ml containing 0.108 ug of silver ion or a concentration of 5.32 ppm silver. This provides 5.32 ug silver ion per ml of 3D structure.
Procedure: to make 100 ml of Silver PermeaDerm Bio-coat Spray Solution (to make 250 mi as opposed to 100 ml use 2.5 x amounts defined below)
Record weight (+/- 3%) of:
1. Beaker plus magnetic stirring bar
2. Sterile water 100 gm
3. Silver citrate/citric acid solution 0.45 gram
4. MedullaPro (gelatin) 0.5 gm
5. lmmuno-10 (Allo) 1 .0 gm
Procedure - for making silver citrate/citric acid solution:
1 . Dissolve 2.24 grams of USP Citric Acid in 9.0 ml_s of distilled water.
2. Add 72.0 mg of Silver Citrate Hydrate and mix to dissolve.
3. Add above mixture to 10 ml_ volumetric flask and add distilled water to volume.
Procedure (follow standard Trelleborg Batch Record Shop Oder instructions and record keeping)
1. Add 100 ml of H2O to beaker w/ stirring bar and bring temperature to 60 degrees C
2. Gradually add 0.5 mg of MedullaPro (gelation) until fully dissolved
3. Gradually add 1 .0 mg of lmmuno-10 (Allo) until fully dissolved
4. Discontinue heating the solution
5. When temperature of solution has cooled about 10 degrees C: gradually add 0.45 grams of silver citrate/citric acid solution until fully dissolved
6. Correct for loss of H2O - same procedure as described in current Trelleborg “Batch Record Shop Order”
Tests of the Efficacy of Preferred Embodiment
TEST 1
Procedure:
The Silver Citrate PRDM C 5” x 57Lot SO 63331 RD pads were digested in standard manner and analyzed by ICPMS to determine silver content per cm2 in the 5” x 5” pads. Result:
Test 1 : 0.000580 ug Silver I cm2 Test 2: 0.000580 ug Silver I cm2 Test 3: 0.000414 ug Silver I cm2 Test 4: 0.000580 ug Silver/ cm2 The expected amount of silver I cm2 on the pads tested is 0.108 ug Silver/ cm2. The recovery was approximately 0.5%% of the expected amount using this method. We were not sure if the low recovery was due to the sample being low in silver or if the testing methodology was in error. Other digestion methods produced similar low silver concentration results in the pads tested (Tests 5 to 9 results similar or less than tests 1-4)). After the investigation further into the formulation components of the pads, we assumed that the silver was likely precipitated as silver chloride in the pads and had to be digested and treated as such in the analytical procedure. The method settled on was an ashing method to incinerate all of the organics and to ostensibly remove chloride by conversion into gaseous chlorine and then acid digestion. This procedure was much better and produced the following amount of silver:
Results:
Test 10: 0.0955 ug Silver/ cm2. This is 88% of the expected silver in the sample tested.
Test 11 : Spiked 90ug of Silver into sample: 79 ug recovered of the 90ug spiked (87.8% recovery).
Conclusion: The Silver Citrate PRDM C 5” x 5”/Lot SO 63331 RD product has silver in the form of silver chloride which will still effectively release silver ion but may require a higher amount of silver citrate to provide the antibiotic efficacy in a timely manner.
TEST 2:
Antibiotic Effectiveness of Silver Citrate PRDM C 5” x 5 ’’/Lot SO 63331 RD
Procedure:
The Silver Citrate PRDM C 5” x 57Lot SO 63331 RD was placed in a tube with 25 ml_s DI water and solicited for 1 hour. After solication, the membrane was transferred into a beaker and heated to boiling for 30 minutes with constant stirring. The volume was reduced to 10 ml_s and split into 2 x 5 ml_s portions. To one of the tubes an additional 45 ug of silver was added. The two samples were then tested against an inoculum of Staphylococcus Epidermis for 7 days to investigate the reduction in colonies.
Conclusions: The addition of 90ug silver per Silver Citrate PRDM C 5” x 57Lot SO 63331 RD sheet is the equivalent of 5 x the original content of the product (17.39 ug silver I cm2). Due to the obvious binding of the silver with the chloride in the Silver Citrate PRDM C 5” x 57Lot SO 63331 RD sheet formulation, it was determined to add 5 x the original amount as the silver chloride slowly releases the silver ion and to provide an effective rate of antibiotic, it may be necessary to increase the silver content of the product by this amount. It was seen that the added amount which was an amount 5 x the original amount was effective in reducing the bacteria level by greater than 99.9% whereas in the same time period, the original formulation reduced the level of bacteria by 97.5%.
Summary of Test Results for Antibiotic Efficacy of Preferred Embodiment
Silver ion is a double-edge sword in that it can kill host cells as well as unwanted microbes that interfere with wound healing. The
FDA requires sufficient silver to effectively reduce the microbial bioburden to enable efficient healing. Goa I: kill required amount of microbes while doing minimal harm to host tissue.
Original formulation is a single step BioDot Spray operation onto the 3D structure of PermeaDerm procedure:
1 . A silver Citrate/Citric Acid Solution is prepared; a. Dissolve 2.24 grams of USP Citric Acid in 9 ml. of distilled water. b. Add 72.0 mg of Silver Citrate Hydrate and mix to dissolve. c. Add above mixture to ml. volumetric flask and add distilled water to volume.
2. Procedure to make Silver Citrate PermeaDerm Spray solution - 6 microliter of this solution is applied per sq. cm. of the 3D nylon side of Silver PermeaDerm: a. Add 100 ml. of D. I. water to beaker w/ stirring bar and bring temperature to 60 degrees C. b. Gradually add 0.5 mg of MedullaPro (gelatin)until fully dissolved. c. Gradually add 1 .0 mg of lmmuno-10 (Aloe) until fully dissolved. d. Discontinue heating the solution. e. When temperature of solution has cooled about 10 degrees C: gradually add 0.45 grams of Silver Citrate/Citric Acid Solution until fully dissolved.
f. Correct for loss of water - same procedure as described in current production “Batch Record Shop Order.” g. Apply 3 microliter per sq. cm. of this solution to the 3D nylon structure to make Silver PermeaDerm.
After Silver PermeaDerm prototypes using the original formulation was manufactured and sterilized with 25 kGy of E Beam the apparent amount of silver present was substantially lower than expected. A concern that the silver might irreversibly be bound to the gelatin or Aloe and unavailable to reduce bacterial bioburden in the wound or in the 3D structure of Silver PermeaDerm.
Preferred formulation for Silver PermeaDerm is a two-step process with following objectives:
1 . A recoverable amount of silver ion from the sterile Silver PermeaDerm biocoat that correlated with the amount of silver applied per sterilization.
2. An amount of silver ion that would effectively reduce the microbial bioburden as required by FDA.
3. An amount of silver ion that minimally harms the host tissue.
The Preferred formulation process:
• The formulation for making Silver PermeaDerm is a two-step biocoat process using the BioDot XYZ spray system. The first step is our Standard method of adding a gelatin/Aloe biocoat (6 microlite per sq.
cm. of PermeaDerm) to the 3D surface of PermeaDerm and dried per normal protocol. After the application of the 1 st gelatin/Aloe biocoat and drying (normal protocol) the 2nd biocoat of a silver citrate/citric acid solution (3 microliter per sq. cm. of PermeaDerm) is applied to the 3D surface of PermeaDerm and dried per normal protocol.
• Desire 3 uL (2n<^ biocoat of Silver Citrate/Citric Acid solution Spray Solution) to dispense 0.54 ug of silver ion or 0.885 ug of silver citrate monohydrate per each square cm surface of PermeaDerm 3D which faces the wound. This concentration is enough to kill 100,000 colony forming units per ml Staphylococcus epidermis at 7, 14 and 21 days. The solution appears stable, has minimal turbidity (as measured at 660 nm) and the silver ion concentration is constant over at least a one month.
• T o make 250 ml_ of Silver Citrate Solution (to deliver 5x the amount (as opposed to formulation on October 27, 2020) of silver ion (0.54 ug per sq. cm in 3 uL) Record weight (+/- 1 %) of:
1 . Beaker plus magnetic stirring bar
2. Sterile water 250 g
3. Silver citrate 74.15 mg
4. USP Citric Acid 56.0 gm
• Procedure (follow standard Trelleborg Batch Record Shop Oder instructions and record keeping)
1 . Add 200 ml_ of H O to beaker w/ stirring bar. Keep constant stirring.
2. Gradually add 56.00 g of citric acid until fully dissolved
3. Gradually add 74.15 mg of silver citrate until fully dissolved
4. When dissolved, add to 250 ml_ volumetric flask and bring to 250 ml_ volume with distilled water.
5. When complete, store at refrigerated temperature (4°C ± 1 °C) for 30 days. After 30 days, filter and weigh filtrate to determine any precipitation. Also, observe solution for cloudiness or any other signs of precipitation of the silver citrate.
6. Apply 5 microliter of this solution to the 3D surface of Standard PermeaDerm to make Silver PermeaDerm
The present invention is a wound closure device that provides an oxygenated, moist but not wet healing environment which by not being wet minimizes bacterial proliferation and optimizes growth of healthy host tissue. The presence of silver ion in the 3D structure of PermeaDerm further enables reduction of harmful bacteria and other microbes.
The new, preferred formulation contained 5X the amount of silver as the original formulation and effectively reduced the bacterial level by 99.9% as compared to the original earlier formulation with 97.9% reduction.
This is the preferred embodiment of the invention. The technology to create this invention is listed as the preferred embodiment of this invention,
but other methods are possible and are within the contemplation of this patent.
Claims
1. A bilaminate cured silicone/nylon material, the silicone/nylon material comprised of two layers of material, the first layer of material comprised of a silicone membrane, the second layer comprised of a knitted nylon fabric, the two layers combined together with a combination means such that the two layers form a single structure, the preferred combination method is heating, the first layer possessing a plurality of slits in its surface, said slits made after the two layers are combined, said slits in a regular pattern, the regular pattern comprising a parallel vertical orientation, said first layer and said second layer treated with a coating comprised of one or more medicinal or therapeutic substances, said medicinal or therapeutic substances including a solution of 8 parts per million (ppm) of silver citrate as an anti-microbial, said silver citrate layer having an anti-microbial effect on up to 99.7% of infectious bacteria, the porosity of said bilaminate cured silicone/nylon material minimized to essentially zero porosity in the mode where no stretching tension is exerted on the bilaminate cured silicone/nylon material, the porosity of said bilaminate cured silicone/nylon material variable proportional to the amount of stretching tension and the direction in which
29
said stretching tension is placed on the bilaminate cured silicone/nylon material,
The gas permeability of said bilaminate cured silicone/nylon material such that when placed over a wound, it acts as a wound oxygenator, said second layer of said material with a preferred range of thickness of 15/1 denier knitted nylon of an average of 0.0080” with STDEV of 0.0008”.
2. A bilaminate cured silicone/nylon material as in Claim 1 where there is an additional component of salinomycin, native high molecular weight collagen, and Mafenide Acetate in the biological coating.
3. A bilaminate cured silicone/nylon material as in Claim 1 using a denier virgin nylon filament of 15/2 or 15/3 with range of thickness 0.0040” to 0.0095”.
4. A bilaminate cured silicone/nylon material as in Claim 1 where said coating is a single layer of biological substances comprised of pure Aloe and BSE free gelatin, or a mixture of pure Aloe, BSE free gelatin and ECM, and where said coating interacts with a wound to stimulate the rate of healing while adherent to the wound, the coating deposited directly on the woven fabric, said coating chemically stable for at least three years at room temperature.
30
5. A method of manufacturing the bilaminate cured silicone/nylon material as in Claim 1 , comprised of the additional steps of, making silver citrate/citric acid solution by dissolving 2.24 grams of USP citric Acid in 9.0 ml_s of distilled water, adding 72.0 mg of silver citrate hydrate and mix to dissolve, adding above mixture to a 10 ml_ volumetric flask and adding distilled water to volume, further making 100 ml of Silver PermeaDerm Bio-coat Spray Solution which requires the following, beaker plus magnetic stirring bar, sterile water 100 gm, silver citrate/citric acid solution 0.45 gram,
MedullaPro TM(gelatin) 0.5 gm, lmmuno-10 (AlloTM) 1.0 gm, then adding 100 ml of H2O to beaker w/ stirring bar and bringing temperature to 60 degrees C, gradually adding 0.5 mg of MedullaPro TM (gelation) until fully dissolved, gradually adding 1 .0 mg of lmmuno-10 (Allo)TM until fully dissolved,
then discontinue heating the solution, when temperature of solution has cooled 10 degrees C, gradually adding 0.45 grams of silver citrate/citric acid solution until fully dissolved, then correct for loss of H2O, then applying 6 microliter per sq. cm. of this solution to the 3D nylon structure to make the bilaminate cured silicone/nylon material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/060228 WO2023091145A1 (en) | 2021-11-20 | 2021-11-20 | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/060228 WO2023091145A1 (en) | 2021-11-20 | 2021-11-20 | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023091145A1 true WO2023091145A1 (en) | 2023-05-25 |
Family
ID=86397628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/060228 WO2023091145A1 (en) | 2021-11-20 | 2021-11-20 | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023091145A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034751A (en) * | 1975-11-24 | 1977-07-12 | International Paper Company | Polymeric sheets as synthetic medical dressings or coverings for wounds |
US4725279A (en) * | 1979-01-22 | 1988-02-16 | Sterling Drug Inc. | Bio compatible and blood compatible materials and methods |
WO2020232456A2 (en) * | 2019-05-13 | 2020-11-19 | Woodroof E Aubrey | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
WO2020231463A1 (en) * | 2019-05-13 | 2020-11-19 | Woodroof E Aubrey | Improved skin substitute adherence, stretchability, and compliance for skin substitutes |
-
2021
- 2021-11-20 WO PCT/US2021/060228 patent/WO2023091145A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034751A (en) * | 1975-11-24 | 1977-07-12 | International Paper Company | Polymeric sheets as synthetic medical dressings or coverings for wounds |
US4725279A (en) * | 1979-01-22 | 1988-02-16 | Sterling Drug Inc. | Bio compatible and blood compatible materials and methods |
WO2020232456A2 (en) * | 2019-05-13 | 2020-11-19 | Woodroof E Aubrey | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
WO2020231463A1 (en) * | 2019-05-13 | 2020-11-19 | Woodroof E Aubrey | Improved skin substitute adherence, stretchability, and compliance for skin substitutes |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10500300B2 (en) | Multi-layer wound care product with perforated release layer | |
JP2875469B2 (en) | Wound dressing | |
US6399091B1 (en) | Wound dressing for the controlled release of active substance to wounds, and process for its manufacture | |
ES2574207T3 (en) | Dressing with a layer of biocellulose prepared to adsorb bacteria | |
EA010316B1 (en) | Wound dressing based on microbial-derived cellulose, use thereof and kit containing thereof | |
CN111803697A (en) | Preparation method of drug-loaded sodium alginate/gelatin composite hydrogel type band-aid | |
RU2437681C1 (en) | Wound covering with therapeutic action | |
CN111068103B (en) | Long-acting antibacterial gel dressing for operation wound and preparation method thereof | |
JP6290184B2 (en) | Wound dressing | |
CN110859989B (en) | Liquid band-aid and preparation method thereof | |
CN106110369A (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
US20050181025A1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
WO2023091145A1 (en) | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity | |
RU2281088C2 (en) | Porous spongy cellulose material for wound treatment | |
WO2020232456A2 (en) | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity | |
CN112891605A (en) | Preparation method of ozone alginate antibacterial functional wound dressing | |
EP1289457A1 (en) | Wound dressing | |
CN111481733A (en) | Biological medicine wound surface dressing | |
CN110917339A (en) | Lysostaphin gel and application thereof in MRSA infected wound surface | |
RU2312658C1 (en) | Film-forming aerosol for wound protection in treatment and method for its using | |
RU2732156C2 (en) | Sublimation-dried haemostatic sponge with antimicrobial (bactericidal) effect and a method for production thereof | |
BR102015029357A2 (en) | THE USE OF BANDAGES AND MEMBRANES PRODUCED WITH QUITOSAN AND COMBINED DERIVATIVES WITH VARIOUS ADDITIVES IN THE REGENERATION OF INJURED FABRICS AND HEALING | |
EP4079340A1 (en) | A dressing comprising an antimicrobial coating | |
CN218552772U (en) | Dressing subsides for skin restoration | |
EP1297059A1 (en) | Films and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21964956 Country of ref document: EP Kind code of ref document: A1 |